Sakar Healthcare – Product Portfolio of 155 Formulations

Reading Time: 13 minutes

Dark Horse Stocks Home Page | Twitter Profile | Join Their Telegram Channel

Current market Price-: Rs 173

Sakar healthcare is just 15 years, extremely small company with market cap of 286 crores engaged in manufacturing of various Pharmaceutical products.

The company also operates as a contract development and manufacturing organization (CDMO) for various leading pharmaceutical companies.

Sakar is one the fastest growing pharmaceutical companies in India, engaged in manufacturing and marketing of premium medicines with a product portfolio of 155 formulations in more than 23 therapeutic areas.

Established in the year 2004, Sakar is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections.

Sakar is managed by a team of professionals with an endeavour to offer Quality Pharmaceutical & Health Care Products in various countries.

The Liquid & Lyophilised Injection unit (small volume parenterals in ampoules and vials) at Sakar Healthcare has been EU GMP approved and all four state of the art manufacturing units are certified by ISO 9001:2015 BVQI , WHO-GMP, cGMP, in addition to the approvals by ‘National Drug Authority’ of Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe(MCAZ), Cambodia, Vietnam, Malawi, Namibia, Nigeria, Cote d’ivoire, Philippines, Peru.

Also Read on FinMedium:  Case study of a 33 bagger whose sales grew at just 6% CAGR over 5 years – Big Vision Investing

Company also caters to countries like Srilanka, Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, and Costa Rica, Panama, El-salvador, Paraguay, etc.

Source link

Also Read on FinMedium:  Note on the Union Budget 2021-22

Disclaimer: The opinions expressed in this publication are those of the authors. They do not purport to reflect the opinions or views of the FinMedium or its members. The presentation of material therein does not imply the expression of any opinion whatsoever on the part of the FinMedium concerning the legal status of any company, country, area, or territory or of its authorities. For more info. please read our ToU & Privacy Policy here. If you have any concerns regarding this post, please reach out to our grievance officer Ghanisht Nagpal and drop a mail to editor@finmedium.com

Every Wednesday and Saturday, we send Info-Graphic and FinMedium Weekly Digest newsletters to our 25000+ Subscribers.

Join Them Now!


Dark Horse Stocks

Dark Horse Stocks

DHS aims to reach a wider audience by providing them with access to the data. Thereby helping them analyze financial reports and make their own investment decisions.
Please Share Now :)

Leave a Reply

Your email address will not be published. Required fields are marked *